Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center

Itacitinib in Treating Patients with Low Risk Graft Versus Host Disease

This phase II trial studies how well itacitinib works in treating patients with low risk graft versus host disease. Graft versus host disease is the most common serious complication after bone marrow transplant. It occurs when donor immune cells (the graft) attack normal tissue in the recipient’s body. This inflammatory immune system attack can damage the skin, liver, stomach, and / or intestines. Itacitinib may help reduce the inflammation associated with graft versus host disease by blocking the enzymes associated with activating the inflammatory process.
Hematologic
Phase II
Both
Mol. targeted/Immunotherapy/Biologics
Itacitinib
Kitko, Carrie
National
Vanderbilt University
08-27-2019
Treatment
VICCPED1912
NCT03846479

Eligibility

Not Available
Not Available
NO
Inclusion Criteria:

Newly diagnosed GVHD that meets criteria for Minnesota standard risk.

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: